Changes of Hemostatic Factors in Children with Acute Lymphoblastic Leukemia Receiving Combined Chemotherapy Including High Dose Methylprednisolone and L-Asparaginase
Authors:
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 33 (3-4) , 361-364
Abstract
In this study, protein C (PC), protein S (PS), heparin cofactor II (HCFII), prothrombin fragment 1+2 (PF 1,2), thrombin-antithrombin III complex (TAT), von Willebrand factor (vWF) and thrombomodulin (TM) were investigated in 19 patients with acute lymphoblastic leukemia, (ALL) receiving combined chemotherapy including L-asparaginase (L-ASP) and high dose methylprednisolone (HDMP). HDMP was administered in doses of 30 mg/kg/day for 7 days, and 20 mg/kg/day for another 7 days. In order to evaluate the effect of HDMP on the hemostatic system, the 8 patients studied here received HDMP (30 mg/kg/day) therapy for 4 days before the combined chemotherapy. These parameters were also studied in 12 healthy children as a control group. PC levels were normal in the patients while PS levels were decreased both before and after combined chemotherapies. Patients with ALL have laboratory signs of coagulation activation such as PF 1,2, TAT prior to initiation of chemotherapy. With combined chemotherapy, TAT levels were found to be normal while PF1,2 were not. TM levels were found to be increased both before and after therapies whereas HCFII and vWF levels were not different from those of the control group. The short course of HDMP therapy did not prominently influence these hemostatic parameters. These results indicate that both the malignant process and the drugs used in combined chemotherapy cause a decrease in natural inhibitors and an increase in procoagulant activity and endothelial injury. These hemostatic changes may contribute to a thrombotic tendency in the patients with ALL.Keywords
This publication has 11 references indexed in Scilit:
- Anticoagulant Properties of the Vascular EndotheliumThrombosis and Haemostasis, 1997
- High‐dose methylprednisolone for children with acute lymphoblastic leukemia and unfavorable presenting featuresEuropean Journal of Haematology, 1997
- COAGULATION DISORDERS IN CANCERHematology/Oncology Clinics of North America, 1996
- Hypercoagulability and thrombosisMedical Clinics of North America, 1994
- Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiencyBlood, 1994
- Plasma Thrombomodulin as a Marker of Vascular Injuries in Collagen Vascular DiseasesAmerican Journal of Clinical Pathology, 1994
- Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L‐asparaginase during induction therapy: A retrospective studyEuropean Journal of Haematology, 1992
- Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyThe Lancet, 1991
- The coagulopathy of childhood leukemia thrombin activation or primary fibrinolysis?Cancer, 1990
- Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemiaBritish Journal of Haematology, 1986